^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Uterine Cancer |
| Drug: | Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Excerpt:
...- All patients must have a somatic PIK3CA gene mutation (i.e., R88Q in exon 1, N345K in exon 4, C420R in exon 7, E542K, E545X [E545A, E545D, E545G, and E545K], Q546X [Q546E, Q546K, Q546L, and Q546R] in exon 9, and M1043I, H1047X [H1047L, H1047R, and H1047Y], or G1049R in exon 20) in a representative primary or metastatic tumor sample confirmed by the Roche COBAS PIK3CA Mutation Test at Q^2 Solutions...
Trial ID:
Source:
Title:
Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.
Excerpt:
35 pts were enrolled (from 8/2/18 to 12/27/18), of which, 28 pts were available for analysis...Partial responses were seen in uterine cancer, clear cell carcinoma of anterior abdominal wall, and liposarcoma….Copanlisib showed meaningful clinical activity across various tumors with PIK3CA mutation in the late-line refractory setting.
DOI:
10.1200/JCO.2020.38.15_suppl.3506
Trial ID:
